10 research outputs found
Controlling hydrogen evolution on iron electrodes
Aiming to develop a cost effective means to store large amounts of electric energy, NiFe batteries were produced and tested under galvanostatic conditions at room temperature. Multiple regression analysis was conducted to develop predictive equations that establish a link between hydrogen evolution and electrode manufacturing conditions, over a wide range of electrode/electrolyte systems. Basically, the intent was to investigate the incidence of lithium hydroxide and potassium sulphide as electrolyte additives on cell performance. With this in mind, in-house built Fe/FeS based electrodes were cycled against commercially available nickel electrodes on a three electrode cell configuration. A 3 × 4 full factorial experimental design was proposed to investigate the combined effect of the aforementioned electrolyte additives on cell performance. As a consequence, data from 144 cells were finally used in conducting the analysis and finding the form of the predictive equations. Our findings suggest that at the level of confidence alpha = 0.05, the presence of relatively large amounts of the soluble bisulphide would enhance the performance of the battery by reducing electrolyte decomposition
Multiple Regression Analysis in the Development of NiFe Cells as Energy Storage Solutions for Intermittent Power Sources Such as Wind or Solar
Multiple regression analysis was used to investigate the effect of bismuth sulphide and iron sulphide as anode additives for NiFe cells. With this in mind, in-house made Fe/FeS/Bi2S3 based electrodes were cycled against commercially available nickel electrodes. A simplex centroid design was used to investigate the combined effects of any of the aforementioned additives on cell performance. The manuscript ends with an initial look at electrolyte systems as a means to further improve the performance of our cells. Finally, our findings support the idea that HS- ions improve the overall performance of NiFe cells
Aqueous batteries as grid scale energy storage solutions
Energy storage technologies are required to make full use of renewable energy sources, and electrochemical
cells offer a great deal flexibility in the design of energy systems. For large scale electrochemical
storage to be viable, the materials employed and device production methods need to be low cost, devices
should be long lasting and safety during operation is of utmost importance. Energy and power densities
are of lesser concern. For these reasons, battery chemistries that make use of aqueous electrolytes are
favorable candidates where large quantities of energy need to be stored. Herein we describe several
different aqueous based battery chemistries and identify some of the research challenges currently
hindering their wider adoption. Lead acid batteries represent a mature technology that currently dominates
the battery market, however there remain challenges that may prevent their future use at the
large scale. Nickel–iron batteries have received a resurgence of interest of late and are known for their
long cycle lives and robust nature however improvements in efficiency are needed in order to make them
competitive. Other technologies that use aqueous electrolytes and have the potential to be useful in
future large-scale applications are briefly introduced. Recent investigations in to the design of nickel–iron
cells are reported with it being shown that electrolyte decomposition can be virtually eliminated by
employing relatively large concentrations of iron sulfide in the electrode mixture, however this is at the
expense of capacity and cycle life
Multivariate investigation of parameters in the development and improvement of NiFe cells
In this article, we use a surface response approach to investigate the effect of bismuth sulphide as well as the compositions of PTFE in the overall columbic efficiency of a NiFe cell battery. Our results demonstrate that while bismuth sulphide favours the process of charge/discharge of a NiFe cell, the use of metallic bismuth only marginally influences coulombic efficiency. In addition we had found that the presence of the soluble bisulfide anion is not sufficient to increase coulombic efficiency in NiFe cells. © 2014 The Authors. Published by Elsevier B.V
Towards the development of safe and commercially viable nickel–iron batteries: improvements to Coulombic efficiency at high iron sulphide electrode formulations
Porous magnesium for hydrogen storage
EThOS - Electronic Theses Online ServiceGBUnited Kingdo
The Effect of Electrolyte Additives on the Performance of Iron Based Anodes for NiFe Cells
Enhancement of Electricity Production in Microbial Fuel Cells Using a Biosurfactant-Producing Co-Culture
Microbial fuel cells are bio-electrochemical devices that enable the conversion of chemical energy into bioelectricity. In this manuscript, the use of biosurfactants (Tween 80 and surfactin) and the effect of coculturing E. coli and L. plantarum were used to investigate the generation of bioelectricity coming from an H-type microbial fuel cell. In this setup, E. coli acts as an electron donor while L. plantarum acts as an in situ biosurfactant producer. It was observed that the use of exogenous surfactants enhanced electricity production compared to conventional E. coli cultures. The utilization of Tween 80 and surfactin increased the power generation from 204 µW m−2 to 506 µW m−2 and 577 µW m−2, respectively. Furthermore, co-culturing E. coli and L. plantarum also resulted in a higher power output compared to pure cultures (132.8% more when compared to using E. coli alone and 68.1% more when compared to using L. plantarum alone). Due to the presence of surfactants, the internal resistance of the cell was reduced. The experimental evidence collected here clearly indicates that the production of endogenous surfactants, as well as the addition of exogenous surfactants, will enhance MFC electricity production
Health-status outcomes with invasive or conservative care in coronary disease
BACKGROUND In the ISCHEMIA trial, an invasive strategy with angiographic assessment and revascularization did not reduce clinical events among patients with stable ischemic heart disease and moderate or severe ischemia. A secondary objective of the trial was to assess angina-related health status among these patients. METHODS We assessed angina-related symptoms, function, and quality of life with the Seattle Angina Questionnaire (SAQ) at randomization, at months 1.5, 3, and 6, and every 6 months thereafter in participants who had been randomly assigned to an invasive treatment strategy (2295 participants) or a conservative strategy (2322). Mixed-effects cumulative probability models within a Bayesian framework were used to estimate differences between the treatment groups. The primary outcome of this health-status analysis was the SAQ summary score (scores range from 0 to 100, with higher scores indicating better health status). All analyses were performed in the overall population and according to baseline angina frequency. RESULTS At baseline, 35% of patients reported having no angina in the previous month. SAQ summary scores increased in both treatment groups, with increases at 3, 12, and 36 months that were 4.1 points (95% credible interval, 3.2 to 5.0), 4.2 points (95% credible interval, 3.3 to 5.1), and 2.9 points (95% credible interval, 2.2 to 3.7) higher with the invasive strategy than with the conservative strategy. Differences were larger among participants who had more frequent angina at baseline (8.5 vs. 0.1 points at 3 months and 5.3 vs. 1.2 points at 36 months among participants with daily or weekly angina as compared with no angina). CONCLUSIONS In the overall trial population with moderate or severe ischemia, which included 35% of participants without angina at baseline, patients randomly assigned to the invasive strategy had greater improvement in angina-related health status than those assigned to the conservative strategy. The modest mean differences favoring the invasive strategy in the overall group reflected minimal differences among asymptomatic patients and larger differences among patients who had had angina at baseline
Initial invasive or conservative strategy for stable coronary disease
BACKGROUND Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain. METHODS We randomly assigned 5179 patients with moderate or severe ischemia to an initial invasive strategy (angiography and revascularization when feasible) and medical therapy or to an initial conservative strategy of medical therapy alone and angiography if medical therapy failed. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. A key secondary outcome was death from cardiovascular causes or myocardial infarction. RESULTS Over a median of 3.2 years, 318 primary outcome events occurred in the invasive-strategy group and 352 occurred in the conservative-strategy group. At 6 months, the cumulative event rate was 5.3% in the invasive-strategy group and 3.4% in the conservative-strategy group (difference, 1.9 percentage points; 95% confidence interval [CI], 0.8 to 3.0); at 5 years, the cumulative event rate was 16.4% and 18.2%, respectively (difference, 121.8 percentage points; 95% CI, 124.7 to 1.0). Results were similar with respect to the key secondary outcome. The incidence of the primary outcome was sensitive to the definition of myocardial infarction; a secondary analysis yielded more procedural myocardial infarctions of uncertain clinical importance. There were 145 deaths in the invasive-strategy group and 144 deaths in the conservative-strategy group (hazard ratio, 1.05; 95% CI, 0.83 to 1.32). CONCLUSIONS Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a median of 3.2 years. The trial findings were sensitive to the definition of myocardial infarction that was used